chrisvoncsefalvay/vaers-narrative-generation huggingface dataset:
Age: 20.0
Sex: M
Vaccine: FLUN3, HEPAB, MMR, MNQ, PPV
Symptoms: Adenovirus test, Amphetamines negative, Balance disorder, Barbiturates negative, Blood culture negative
Clinical narrative: This report to VAERS provides the following narrative: A spontaneous report has been received from VAERS concerning a 20 years old Male patient. The patient's concurrent disease included environmental allergies. Family history included bipolar. Patient received FLUMIST (intranasal) on 18-Feb-2009. Per the patient he received these vaccinations on 19-Feb-2009 or 20-Feb-2009 (he arrived on 18-Feb-2009). On 27-Feb-2009 the patient noted a dry cough. On 02-Mar-2009 the patient reported sick. Call with a productive cough and rhinorrhea. He denied sore throat, earache, fever, N.V., diarrhea, headache or decreased appetite. He was treated with SUDAFED, MOTRIN and MUCINEX. Also, noted at the visit was paronychia middle finger/bilateral which was treated with KEFLEX. On 04-Mar-2009 the patient noted numbness of his right forearm which progressed to his right hand/fingers then to his right shoulder by 06-Mar-2009. He had minimal weakness of his UE. By 06-Mar-2009 he also noted numbness of his left arm/hand/fingers/shoulder and weakness in his lower legs. On 07-Mar-2009 the pt also noted numbness from his anterior neck to his chest and his feet felt cold and tingly. The numbness radiated to his back on 08-Mar-2009. By 09-Mar-2009 the patient was barely able to move his legs, he had problems with balance and his arms were weak. He was seen in Sick Call and diagnosed with and treated for dehydration. By 12-Mar-2009 the patient was Worse, he was having hard time walking independently his UE were weak he hands and feet were completely numb. The patient states he was sent to the ER and admitted to hospital on 13-Mar-2009. Treated with IVIG for 3 days and patient. Discharged on 20-Mar-2009. On 03-Apr-2009 residual numbness on bilateral great toes. Diagnosis was Guillain-Barre syndrome. Records reveal patient experienced dry cough on 27-Feb-2009, then developed productive cough, rhinorrhea, seen in clinic. Patient lab results were as follows: 13-Mar-2009 Mycoplasma sp. Ab IgG, 3.07 (H); Mycoplasma sp. Ab IgM, 166; Streptococcus pneumoniae Ag, urine, negative; Legionella sp. Ab Serum, 1:128; 13-Mar-2009 2345, Blood culture, no growth after 48 hrs. no growth in 5 days; 14-Mar-2009 Drug Screen Urine; Amphetamines, negative; Benzodiazepines, negative; Cocaine, negative; Opiates, negative; Cannabinoids, negative; Barbiturates, negative; Phencyclidine, negative. 14-Mar-2009: Sputum, many gram positive cocci, many gram negative rods. 14-Mar-2009: Influenza Virus A+B Ag, negative. 14-Mar-2009: Adenovirus Ag, negative; 14 Mar 2009 0302, Respiratory Syncytial Virus Ag, Negative; 14-Mar-2009: Parainfluenza Virus, negative; 14-Mar-2009: Specimen; Throat B. The outcome of the event of Guillain-Barre syndrome was unknown. The reporter assessed the event of Guillain-Barre syndrome to be serious with seriousness criteria of Hospitalised.
Age: 20.0
Sex: M
Vaccine: FLUN3, HEPAB, MMR, MNQ, PPV
Symptoms: Cough, Culture throat, Dehydration, Drug screen, Guillain-Barre syndrome
Clinical narrative: This report to VAERS provides the following narrative: A spontaneous report has been received from VAERS concerning a 20 years old Male patient. The patient's concurrent disease included environmental allergies. Family history included bipolar. Patient received FLUMIST (intranasal) on 18-Feb-2009. Per the patient he received these vaccinations on 19-Feb-2009 or 20-Feb-2009 (he arrived on 18-Feb-2009). On 27-Feb-2009 the patient noted a dry cough. On 02-Mar-2009 the patient reported sick. Call with a productive cough and rhinorrhea. He denied sore throat, earache, fever, N.V., diarrhea, headache or decreased appetite. He was treated with SUDAFED, MOTRIN and MUCINEX. Also, noted at the visit was paronychia middle finger/bilateral which was treated with KEFLEX. On 04-Mar-2009 the patient noted numbness of his right forearm which progressed to his right hand/fingers then to his right shoulder by 06-Mar-2009. He had minimal weakness of his UE. By 06-Mar-2009 he also noted numbness of his left arm/hand/fingers/shoulder and weakness in his lower legs. On 07-Mar-2009 the pt also noted numbness from his anterior neck to his chest and his feet felt cold and tingly. The numbness radiated to his back on 08-Mar-2009. By 09-Mar-2009 the patient was barely able to move his legs, he had problems with balance and his arms were weak. He was seen in Sick Call and diagnosed with and treated for dehydration. By 12-Mar-2009 the patient was Worse, he was having hard time walking independently his UE were weak he hands and feet were completely numb. The patient states he was sent to the ER and admitted to hospital on 13-Mar-2009. Treated with IVIG for 3 days and patient. Discharged on 20-Mar-2009. On 03-Apr-2009 residual numbness on bilateral great toes. Diagnosis was Guillain-Barre syndrome. Records reveal patient experienced dry cough on 27-Feb-2009, then developed productive cough, rhinorrhea, seen in clinic. Patient lab results were as follows: 13-Mar-2009 Mycoplasma sp. Ab IgG, 3.07 (H); Mycoplasma sp. Ab IgM, 166; Streptococcus pneumoniae Ag, urine, negative; Legionella sp. Ab Serum, 1:128; 13-Mar-2009 2345, Blood culture, no growth after 48 hrs. no growth in 5 days; 14-Mar-2009 Drug Screen Urine; Amphetamines, negative; Benzodiazepines, negative; Cocaine, negative; Opiates, negative; Cannabinoids, negative; Barbiturates, negative; Phencyclidine, negative. 14-Mar-2009: Sputum, many gram positive cocci, many gram negative rods. 14-Mar-2009: Influenza Virus A+B Ag, negative. 14-Mar-2009: Adenovirus Ag, negative; 14 Mar 2009 0302, Respiratory Syncytial Virus Ag, Negative; 14-Mar-2009: Parainfluenza Virus, negative; 14-Mar-2009: Specimen; Throat B. The outcome of the event of Guillain-Barre syndrome was unknown. The reporter assessed the event of Guillain-Barre syndrome to be serious with seriousness criteria of Hospitalised.
Age: 20.0
Sex: M
Vaccine: FLUN3, HEPAB, MMR, MNQ, PPV
Symptoms: Hypoaesthesia, Influenza A virus test negative, Influenza B virus test, Legionella test, Malaise
Clinical narrative: This report to VAERS provides the following narrative: A spontaneous report has been received from VAERS concerning a 20 years old Male patient. The patient's concurrent disease included environmental allergies. Family history included bipolar. Patient received FLUMIST (intranasal) on 18-Feb-2009. Per the patient he received these vaccinations on 19-Feb-2009 or 20-Feb-2009 (he arrived on 18-Feb-2009). On 27-Feb-2009 the patient noted a dry cough. On 02-Mar-2009 the patient reported sick. Call with a productive cough and rhinorrhea. He denied sore throat, earache, fever, N.V., diarrhea, headache or decreased appetite. He was treated with SUDAFED, MOTRIN and MUCINEX. Also, noted at the visit was paronychia middle finger/bilateral which was treated with KEFLEX. On 04-Mar-2009 the patient noted numbness of his right forearm which progressed to his right hand/fingers then to his right shoulder by 06-Mar-2009. He had minimal weakness of his UE. By 06-Mar-2009 he also noted numbness of his left arm/hand/fingers/shoulder and weakness in his lower legs. On 07-Mar-2009 the pt also noted numbness from his anterior neck to his chest and his feet felt cold and tingly. The numbness radiated to his back on 08-Mar-2009. By 09-Mar-2009 the patient was barely able to move his legs, he had problems with balance and his arms were weak. He was seen in Sick Call and diagnosed with and treated for dehydration. By 12-Mar-2009 the patient was Worse, he was having hard time walking independently his UE were weak he hands and feet were completely numb. The patient states he was sent to the ER and admitted to hospital on 13-Mar-2009. Treated with IVIG for 3 days and patient. Discharged on 20-Mar-2009. On 03-Apr-2009 residual numbness on bilateral great toes. Diagnosis was Guillain-Barre syndrome. Records reveal patient experienced dry cough on 27-Feb-2009, then developed productive cough, rhinorrhea, seen in clinic. Patient lab results were as follows: 13-Mar-2009 Mycoplasma sp. Ab IgG, 3.07 (H); Mycoplasma sp. Ab IgM, 166; Streptococcus pneumoniae Ag, urine, negative; Legionella sp. Ab Serum, 1:128; 13-Mar-2009 2345, Blood culture, no growth after 48 hrs. no growth in 5 days; 14-Mar-2009 Drug Screen Urine; Amphetamines, negative; Benzodiazepines, negative; Cocaine, negative; Opiates, negative; Cannabinoids, negative; Barbiturates, negative; Phencyclidine, negative. 14-Mar-2009: Sputum, many gram positive cocci, many gram negative rods. 14-Mar-2009: Influenza Virus A+B Ag, negative. 14-Mar-2009: Adenovirus Ag, negative; 14 Mar 2009 0302, Respiratory Syncytial Virus Ag, Negative; 14-Mar-2009: Parainfluenza Virus, negative; 14-Mar-2009: Specimen; Throat B. The outcome of the event of Guillain-Barre syndrome was unknown. The reporter assessed the event of Guillain-Barre syndrome to be serious with seriousness criteria of Hospitalised.
Age: 20.0
Sex: M
Vaccine: FLUN3, HEPAB, MMR, MNQ, PPV
Symptoms: Mobility decreased, Muscular weakness, Mycoplasma test, Paraesthesia, Paronychia
Clinical narrative: This report to VAERS provides the following narrative: A spontaneous report has been received from VAERS concerning a 20 years old Male patient. The patient's concurrent disease included environmental allergies. Family history included bipolar. Patient received FLUMIST (intranasal) on 18-Feb-2009. Per the patient he received these vaccinations on 19-Feb-2009 or 20-Feb-2009 (he arrived on 18-Feb-2009). On 27-Feb-2009 the patient noted a dry cough. On 02-Mar-2009 the patient reported sick. Call with a productive cough and rhinorrhea. He denied sore throat, earache, fever, N.V., diarrhea, headache or decreased appetite. He was treated with SUDAFED, MOTRIN and MUCINEX. Also, noted at the visit was paronychia middle finger/bilateral which was treated with KEFLEX. On 04-Mar-2009 the patient noted numbness of his right forearm which progressed to his right hand/fingers then to his right shoulder by 06-Mar-2009. He had minimal weakness of his UE. By 06-Mar-2009 he also noted numbness of his left arm/hand/fingers/shoulder and weakness in his lower legs. On 07-Mar-2009 the pt also noted numbness from his anterior neck to his chest and his feet felt cold and tingly. The numbness radiated to his back on 08-Mar-2009. By 09-Mar-2009 the patient was barely able to move his legs, he had problems with balance and his arms were weak. He was seen in Sick Call and diagnosed with and treated for dehydration. By 12-Mar-2009 the patient was Worse, he was having hard time walking independently his UE were weak he hands and feet were completely numb. The patient states he was sent to the ER and admitted to hospital on 13-Mar-2009. Treated with IVIG for 3 days and patient. Discharged on 20-Mar-2009. On 03-Apr-2009 residual numbness on bilateral great toes. Diagnosis was Guillain-Barre syndrome. Records reveal patient experienced dry cough on 27-Feb-2009, then developed productive cough, rhinorrhea, seen in clinic. Patient lab results were as follows: 13-Mar-2009 Mycoplasma sp. Ab IgG, 3.07 (H); Mycoplasma sp. Ab IgM, 166; Streptococcus pneumoniae Ag, urine, negative; Legionella sp. Ab Serum, 1:128; 13-Mar-2009 2345, Blood culture, no growth after 48 hrs. no growth in 5 days; 14-Mar-2009 Drug Screen Urine; Amphetamines, negative; Benzodiazepines, negative; Cocaine, negative; Opiates, negative; Cannabinoids, negative; Barbiturates, negative; Phencyclidine, negative. 14-Mar-2009: Sputum, many gram positive cocci, many gram negative rods. 14-Mar-2009: Influenza Virus A+B Ag, negative. 14-Mar-2009: Adenovirus Ag, negative; 14 Mar 2009 0302, Respiratory Syncytial Virus Ag, Negative; 14-Mar-2009: Parainfluenza Virus, negative; 14-Mar-2009: Specimen; Throat B. The outcome of the event of Guillain-Barre syndrome was unknown. The reporter assessed the event of Guillain-Barre syndrome to be serious with seriousness criteria of Hospitalised.
Age: 20.0
Sex: M
Vaccine: FLUN3, HEPAB, MMR, MNQ, PPV
Symptoms: Peripheral coldness, Productive cough, Respiratory syncytial virus test negative, Rhinorrhoea, Sputum culture positive
Clinical narrative: This report to VAERS provides the following narrative: A spontaneous report has been received from VAERS concerning a 20 years old Male patient. The patient's concurrent disease included environmental allergies. Family history included bipolar. Patient received FLUMIST (intranasal) on 18-Feb-2009. Per the patient he received these vaccinations on 19-Feb-2009 or 20-Feb-2009 (he arrived on 18-Feb-2009). On 27-Feb-2009 the patient noted a dry cough. On 02-Mar-2009 the patient reported sick. Call with a productive cough and rhinorrhea. He denied sore throat, earache, fever, N.V., diarrhea, headache or decreased appetite. He was treated with SUDAFED, MOTRIN and MUCINEX. Also, noted at the visit was paronychia middle finger/bilateral which was treated with KEFLEX. On 04-Mar-2009 the patient noted numbness of his right forearm which progressed to his right hand/fingers then to his right shoulder by 06-Mar-2009. He had minimal weakness of his UE. By 06-Mar-2009 he also noted numbness of his left arm/hand/fingers/shoulder and weakness in his lower legs. On 07-Mar-2009 the pt also noted numbness from his anterior neck to his chest and his feet felt cold and tingly. The numbness radiated to his back on 08-Mar-2009. By 09-Mar-2009 the patient was barely able to move his legs, he had problems with balance and his arms were weak. He was seen in Sick Call and diagnosed with and treated for dehydration. By 12-Mar-2009 the patient was Worse, he was having hard time walking independently his UE were weak he hands and feet were completely numb. The patient states he was sent to the ER and admitted to hospital on 13-Mar-2009. Treated with IVIG for 3 days and patient. Discharged on 20-Mar-2009. On 03-Apr-2009 residual numbness on bilateral great toes. Diagnosis was Guillain-Barre syndrome. Records reveal patient experienced dry cough on 27-Feb-2009, then developed productive cough, rhinorrhea, seen in clinic. Patient lab results were as follows: 13-Mar-2009 Mycoplasma sp. Ab IgG, 3.07 (H); Mycoplasma sp. Ab IgM, 166; Streptococcus pneumoniae Ag, urine, negative; Legionella sp. Ab Serum, 1:128; 13-Mar-2009 2345, Blood culture, no growth after 48 hrs. no growth in 5 days; 14-Mar-2009 Drug Screen Urine; Amphetamines, negative; Benzodiazepines, negative; Cocaine, negative; Opiates, negative; Cannabinoids, negative; Barbiturates, negative; Phencyclidine, negative. 14-Mar-2009: Sputum, many gram positive cocci, many gram negative rods. 14-Mar-2009: Influenza Virus A+B Ag, negative. 14-Mar-2009: Adenovirus Ag, negative; 14 Mar 2009 0302, Respiratory Syncytial Virus Ag, Negative; 14-Mar-2009: Parainfluenza Virus, negative; 14-Mar-2009: Specimen; Throat B. The outcome of the event of Guillain-Barre syndrome was unknown. The reporter assessed the event of Guillain-Barre syndrome to be serious with seriousness criteria of Hospitalised.
Age: 20.0
Sex: M
Vaccine: FLUN3, HEPAB, MMR, MNQ, PPV
Symptoms: Streptococcus test
Clinical narrative: This report to VAERS provides the following narrative: A spontaneous report has been received from VAERS concerning a 20 years old Male patient. The patient's concurrent disease included environmental allergies. Family history included bipolar. Patient received FLUMIST (intranasal) on 18-Feb-2009. Per the patient he received these vaccinations on 19-Feb-2009 or 20-Feb-2009 (he arrived on 18-Feb-2009). On 27-Feb-2009 the patient noted a dry cough. On 02-Mar-2009 the patient reported sick. Call with a productive cough and rhinorrhea. He denied sore throat, earache, fever, N.V., diarrhea, headache or decreased appetite. He was treated with SUDAFED, MOTRIN and MUCINEX. Also, noted at the visit was paronychia middle finger/bilateral which was treated with KEFLEX. On 04-Mar-2009 the patient noted numbness of his right forearm which progressed to his right hand/fingers then to his right shoulder by 06-Mar-2009. He had minimal weakness of his UE. By 06-Mar-2009 he also noted numbness of his left arm/hand/fingers/shoulder and weakness in his lower legs. On 07-Mar-2009 the pt also noted numbness from his anterior neck to his chest and his feet felt cold and tingly. The numbness radiated to his back on 08-Mar-2009. By 09-Mar-2009 the patient was barely able to move his legs, he had problems with balance and his arms were weak. He was seen in Sick Call and diagnosed with and treated for dehydration. By 12-Mar-2009 the patient was Worse, he was having hard time walking independently his UE were weak he hands and feet were completely numb. The patient states he was sent to the ER and admitted to hospital on 13-Mar-2009. Treated with IVIG for 3 days and patient. Discharged on 20-Mar-2009. On 03-Apr-2009 residual numbness on bilateral great toes. Diagnosis was Guillain-Barre syndrome. Records reveal patient experienced dry cough on 27-Feb-2009, then developed productive cough, rhinorrhea, seen in clinic. Patient lab results were as follows: 13-Mar-2009 Mycoplasma sp. Ab IgG, 3.07 (H); Mycoplasma sp. Ab IgM, 166; Streptococcus pneumoniae Ag, urine, negative; Legionella sp. Ab Serum, 1:128; 13-Mar-2009 2345, Blood culture, no growth after 48 hrs. no growth in 5 days; 14-Mar-2009 Drug Screen Urine; Amphetamines, negative; Benzodiazepines, negative; Cocaine, negative; Opiates, negative; Cannabinoids, negative; Barbiturates, negative; Phencyclidine, negative. 14-Mar-2009: Sputum, many gram positive cocci, many gram negative rods. 14-Mar-2009: Influenza Virus A+B Ag, negative. 14-Mar-2009: Adenovirus Ag, negative; 14 Mar 2009 0302, Respiratory Syncytial Virus Ag, Negative; 14-Mar-2009: Parainfluenza Virus, negative; 14-Mar-2009: Specimen; Throat B. The outcome of the event of Guillain-Barre syndrome was unknown. The reporter assessed the event of Guillain-Barre syndrome to be serious with seriousness criteria of Hospitalised.
Age: 13.0
Sex: M
Vaccine: FLUN3
Symptoms: Blood creatine phosphokinase normal, Blood immunoglobulin A normal, C-reactive protein normal, Electromyogram, Full blood count normal
Clinical narrative: A report has been received from FDA, concerning a 13 year old male patient. The patient's concurrent diseases included allergy to dogs, allergy to cats and allergy to walnut trees. On 30-Oct-2009, the patient started receiving FLUMIST (intranasal). On 05-Nov-2009, the patient experienced Guillain-Barre syndrome. There was a sudden onset of lower extremity weakness, numbness of thighs and abnormal gait. On 12-Nov-2009, neuro consult records and labs/dx studies were done. Neuro exam noted decreased deep tendon reflexes and LE's. No DC DX was noted. The action taken with FLUMIST and the outcome of Guillain-Barre syndrome was unknown. The reporter considered the event of Guillain-Barre syndrome to be serious due to hospitalization. The patient required emergency room/doctor's visit. Laboratory values and diagnostic test details are available.
Age: 13.0
Sex: M
Vaccine: FLUN3
Symptoms: Gait disturbance, Guillain-Barre syndrome, Hypoaesthesia, Hyporeflexia, Metabolic function test normal
Clinical narrative: A report has been received from FDA, concerning a 13 year old male patient. The patient's concurrent diseases included allergy to dogs, allergy to cats and allergy to walnut trees. On 30-Oct-2009, the patient started receiving FLUMIST (intranasal). On 05-Nov-2009, the patient experienced Guillain-Barre syndrome. There was a sudden onset of lower extremity weakness, numbness of thighs and abnormal gait. On 12-Nov-2009, neuro consult records and labs/dx studies were done. Neuro exam noted decreased deep tendon reflexes and LE's. No DC DX was noted. The action taken with FLUMIST and the outcome of Guillain-Barre syndrome was unknown. The reporter considered the event of Guillain-Barre syndrome to be serious due to hospitalization. The patient required emergency room/doctor's visit. Laboratory values and diagnostic test details are available.
Age: 13.0
Sex: M
Vaccine: FLUN3
Symptoms: Muscular weakness, Nerve conduction studies abnormal, Neurological examination abnormal, Nuclear magnetic resonance imaging spinal normal, Red blood cell sedimentation rate normal
Clinical narrative: A report has been received from FDA, concerning a 13 year old male patient. The patient's concurrent diseases included allergy to dogs, allergy to cats and allergy to walnut trees. On 30-Oct-2009, the patient started receiving FLUMIST (intranasal). On 05-Nov-2009, the patient experienced Guillain-Barre syndrome. There was a sudden onset of lower extremity weakness, numbness of thighs and abnormal gait. On 12-Nov-2009, neuro consult records and labs/dx studies were done. Neuro exam noted decreased deep tendon reflexes and LE's. No DC DX was noted. The action taken with FLUMIST and the outcome of Guillain-Barre syndrome was unknown. The reporter considered the event of Guillain-Barre syndrome to be serious due to hospitalization. The patient required emergency room/doctor's visit. Laboratory values and diagnostic test details are available.
Age: 13.0
Sex: M
Vaccine: FLUN3
Symptoms: Urine analysis normal
Clinical narrative: A report has been received from FDA, concerning a 13 year old male patient. The patient's concurrent diseases included allergy to dogs, allergy to cats and allergy to walnut trees. On 30-Oct-2009, the patient started receiving FLUMIST (intranasal). On 05-Nov-2009, the patient experienced Guillain-Barre syndrome. There was a sudden onset of lower extremity weakness, numbness of thighs and abnormal gait. On 12-Nov-2009, neuro consult records and labs/dx studies were done. Neuro exam noted decreased deep tendon reflexes and LE's. No DC DX was noted. The action taken with FLUMIST and the outcome of Guillain-Barre syndrome was unknown. The reporter considered the event of Guillain-Barre syndrome to be serious due to hospitalization. The patient required emergency room/doctor's visit. Laboratory values and diagnostic test details are available.
Age: 8.0
Sex: F
Vaccine: FLUN3
Symptoms: Guillain-Barre syndrome, Headache, Myalgia
Clinical narrative: This case was received from Regulatory Authority (VAERS) concerning an 8 year old female patient. No concomitant medication and no medical history were provided. The patient had been receiving FLUMIST (intranasal) started on 24-Nov-2010. The patient experienced Guillain-Barre syndrome and headache which started on 26-Nov-2010 and myalgia. Complain of headache and muscle ache later diagnosed and treated for Guillain-Barre syndrome. The outcome of the event of Guillain-Barre syndrome, headache and myalgia was unknown. The reporter assessed the events Guillain-Barre syndrome, headache and myalgia to be serious with seriousness criteria of Hospitalization.
Age: 9.0
Sex: F
Vaccine: FLUN3
Symptoms: CSF test, Guillain-Barre syndrome, Nuclear magnetic resonance imaging brain normal, Nuclear magnetic resonance imaging normal, Nuclear magnetic resonance imaging spinal normal
Clinical narrative: A spontaneous consumer report received from regulatory authority (VAERS), concerns a 9 years old female patient. The patient's medical history included ADHD (attention deficit/hyperactivity disorder). Concomitant medications were not reported. On 11-Jan-2012, the patient received FLUMIST (intranasal). It was reported that patient experienced Guillain-Barre syndrome on 23-Jan-2012. Negative MRI brain and spine, CSF test also reported. At the time of reporting, the event of Guillain-Barre syndrome was ongoing. Reporter assessed the Guillain-Barre syndrome to be serious as hospitalization.
Age: 4.0
Sex: M
Vaccine: FLUN3
Symptoms: Guillain-Barre syndrome, Lumbar puncture abnormal, Nuclear magnetic resonance imaging abnormal
Clinical narrative: A spontaneous health professional report received via regulatory authority (VAERS), concerns a 4 year old male patient. Patient's medical history and concurrent diseases were not reported. Concomitant medications were not reported. On 08-Nov-2010, the patient received FLUMIST (intranasal). It was reported that patient had a Guillain-Barre syndrome which started on 15-Nov-2010. Patient had nuclear magnetic resonance imaging and lumbar puncture with abnormal results. The patient recovered from the event of Guillain-Barre syndrome on an unspecified date. Reporter assessed the Guillain-Barre syndrome to be serious as life threatening and hospitalization.
Age: 9.0
Sex: F
Vaccine: FLUN3
Symptoms: Alanine aminotransferase increased, Anxiety, Areflexia, Arthralgia, Aspartate aminotransferase increased
Clinical narrative: This report to VAERS provides the following narrative: A report has been received from consumer via VAERS concerning a 9 year old female patient. The patient's concurrent disease included allergic rhinitis. Concomitant medications included cetirizine hydrochloride. Patient had been receiving FLUMIST (intranasal) started on 10-Jan-2013. Odd gait when walking, running on 01-Apr-2013. Feet tingled on 02-Apr-2013. Limping on 03-Apr-2013 and began falling frequently. ER on 07-Apr-2013 and diagnosed with Guillain-Barre Syndrome on 08-Apr-2013. The following information was obtained through follow-up and/or provided by the government. 13-Jun-2013 Hospital records and discharge summary received. Service dates 07-Apr-2013 to 16-Apr-2013, 24-Apr-2013 to 09-May-2013. Diagnosis: Guillain-Barre Syndrome, axonal variant, with associated lower extremity weakness, relapse. Acute demyelinating polyneuropathy. Patient diagnosed with GBS 2 weeks prior, clumsiness, difficulties walking, foot numbness/tingling. IVIG administration. Using walker, discharged to outpatient PT/OT. Now presenting with worsening weakness in lower extremities and new tingling in feet. Blurred/double vision and weakness in EOM, CN 6 Palsy. Areflexia lower extremities with weakness in hips, knees, ankles. Back/neck pain. Potential Miller-Fisher. Gabapentin PO. Trouble sleeping. Urinary retention, bladder distended, probable neurogenic bladder. Plasmapheresis catheter placement, PLEX. 6/14/13 Neurology Consultation records received. Service dates 16-Apr-2013 to 02-May-2013. Additional Information Abstracted: Diagnosis: Guillain-Barre Syndrome. Worsening balance, difficulty walking, worsening weakness lower extremities. Weakness noted involving bilateral upper extremities. Emesis, pain in hips and neck, neuropathic pain, headache after IVIG, transient hypotension, anxious. Keratosis pilaris. Plasma exchanges. CT Scan. Full blood work. MRI and spinal tap. The following information was obtained through follow-up and/or provided by the government. 13-Jun-2013, 21-Jun-2013, 24-Jun-2013 Labs and Diagnostics: CSF - Abnormal, Protein 135 mg/dl. CBC / RBC 3.74 M/mm3 (L) HGB 11.0 g/dl (L) HCT 32.4% (L) RDW 16.1% (H) Seg 35.8% (L) Mono 11.0% (H) Lymph 48.6% (H). Sed Rate 86 mm/hr (H). Fibrinogen 143 mg/dl (L). CHEM - Calcium Ionized 1.35 mm/L (H) ALT 68 (H) AST 56 (H). Urinalysis - Cloudy, Leukocytes trace, Amorphous crystals few, Gram Stain positive cocci in pairs, Gram negative coccobacilli. EMG/NCS report with graphs - Abnormal. MRI Spine - Abnormal, enhancement of lumbosacral/cauda equina nerve roots, small cystic benign appearing lesion within pedicle of L3 ve. The outcome of the event of Guillain-Barre syndrome was unknown. The reporter assessed the event to be serious with seriousness criteria of Life threatening and Hospitalization.
Age: 9.0
Sex: F
Vaccine: FLUN3
Symptoms: Asthenia, Back pain, Bacterial test, Balance disorder, Bladder dilatation
Clinical narrative: This report to VAERS provides the following narrative: A report has been received from consumer via VAERS concerning a 9 year old female patient. The patient's concurrent disease included allergic rhinitis. Concomitant medications included cetirizine hydrochloride. Patient had been receiving FLUMIST (intranasal) started on 10-Jan-2013. Odd gait when walking, running on 01-Apr-2013. Feet tingled on 02-Apr-2013. Limping on 03-Apr-2013 and began falling frequently. ER on 07-Apr-2013 and diagnosed with Guillain-Barre Syndrome on 08-Apr-2013. The following information was obtained through follow-up and/or provided by the government. 13-Jun-2013 Hospital records and discharge summary received. Service dates 07-Apr-2013 to 16-Apr-2013, 24-Apr-2013 to 09-May-2013. Diagnosis: Guillain-Barre Syndrome, axonal variant, with associated lower extremity weakness, relapse. Acute demyelinating polyneuropathy. Patient diagnosed with GBS 2 weeks prior, clumsiness, difficulties walking, foot numbness/tingling. IVIG administration. Using walker, discharged to outpatient PT/OT. Now presenting with worsening weakness in lower extremities and new tingling in feet. Blurred/double vision and weakness in EOM, CN 6 Palsy. Areflexia lower extremities with weakness in hips, knees, ankles. Back/neck pain. Potential Miller-Fisher. Gabapentin PO. Trouble sleeping. Urinary retention, bladder distended, probable neurogenic bladder. Plasmapheresis catheter placement, PLEX. 6/14/13 Neurology Consultation records received. Service dates 16-Apr-2013 to 02-May-2013. Additional Information Abstracted: Diagnosis: Guillain-Barre Syndrome. Worsening balance, difficulty walking, worsening weakness lower extremities. Weakness noted involving bilateral upper extremities. Emesis, pain in hips and neck, neuropathic pain, headache after IVIG, transient hypotension, anxious. Keratosis pilaris. Plasma exchanges. CT Scan. Full blood work. MRI and spinal tap. The following information was obtained through follow-up and/or provided by the government. 13-Jun-2013, 21-Jun-2013, 24-Jun-2013 Labs and Diagnostics: CSF - Abnormal, Protein 135 mg/dl. CBC / RBC 3.74 M/mm3 (L) HGB 11.0 g/dl (L) HCT 32.4% (L) RDW 16.1% (H) Seg 35.8% (L) Mono 11.0% (H) Lymph 48.6% (H). Sed Rate 86 mm/hr (H). Fibrinogen 143 mg/dl (L). CHEM - Calcium Ionized 1.35 mm/L (H) ALT 68 (H) AST 56 (H). Urinalysis - Cloudy, Leukocytes trace, Amorphous crystals few, Gram Stain positive cocci in pairs, Gram negative coccobacilli. EMG/NCS report with graphs - Abnormal. MRI Spine - Abnormal, enhancement of lumbosacral/cauda equina nerve roots, small cystic benign appearing lesion within pedicle of L3 ve. The outcome of the event of Guillain-Barre syndrome was unknown. The reporter assessed the event to be serious with seriousness criteria of Life threatening and Hospitalization.
Age: 9.0
Sex: F
Vaccine: FLUN3
Symptoms: Blood fibrinogen decreased, CSF protein increased, Calcium ionised increased, Catheter placement, Clumsiness
Clinical narrative: This report to VAERS provides the following narrative: A report has been received from consumer via VAERS concerning a 9 year old female patient. The patient's concurrent disease included allergic rhinitis. Concomitant medications included cetirizine hydrochloride. Patient had been receiving FLUMIST (intranasal) started on 10-Jan-2013. Odd gait when walking, running on 01-Apr-2013. Feet tingled on 02-Apr-2013. Limping on 03-Apr-2013 and began falling frequently. ER on 07-Apr-2013 and diagnosed with Guillain-Barre Syndrome on 08-Apr-2013. The following information was obtained through follow-up and/or provided by the government. 13-Jun-2013 Hospital records and discharge summary received. Service dates 07-Apr-2013 to 16-Apr-2013, 24-Apr-2013 to 09-May-2013. Diagnosis: Guillain-Barre Syndrome, axonal variant, with associated lower extremity weakness, relapse. Acute demyelinating polyneuropathy. Patient diagnosed with GBS 2 weeks prior, clumsiness, difficulties walking, foot numbness/tingling. IVIG administration. Using walker, discharged to outpatient PT/OT. Now presenting with worsening weakness in lower extremities and new tingling in feet. Blurred/double vision and weakness in EOM, CN 6 Palsy. Areflexia lower extremities with weakness in hips, knees, ankles. Back/neck pain. Potential Miller-Fisher. Gabapentin PO. Trouble sleeping. Urinary retention, bladder distended, probable neurogenic bladder. Plasmapheresis catheter placement, PLEX. 6/14/13 Neurology Consultation records received. Service dates 16-Apr-2013 to 02-May-2013. Additional Information Abstracted: Diagnosis: Guillain-Barre Syndrome. Worsening balance, difficulty walking, worsening weakness lower extremities. Weakness noted involving bilateral upper extremities. Emesis, pain in hips and neck, neuropathic pain, headache after IVIG, transient hypotension, anxious. Keratosis pilaris. Plasma exchanges. CT Scan. Full blood work. MRI and spinal tap. The following information was obtained through follow-up and/or provided by the government. 13-Jun-2013, 21-Jun-2013, 24-Jun-2013 Labs and Diagnostics: CSF - Abnormal, Protein 135 mg/dl. CBC / RBC 3.74 M/mm3 (L) HGB 11.0 g/dl (L) HCT 32.4% (L) RDW 16.1% (H) Seg 35.8% (L) Mono 11.0% (H) Lymph 48.6% (H). Sed Rate 86 mm/hr (H). Fibrinogen 143 mg/dl (L). CHEM - Calcium Ionized 1.35 mm/L (H) ALT 68 (H) AST 56 (H). Urinalysis - Cloudy, Leukocytes trace, Amorphous crystals few, Gram Stain positive cocci in pairs, Gram negative coccobacilli. EMG/NCS report with graphs - Abnormal. MRI Spine - Abnormal, enhancement of lumbosacral/cauda equina nerve roots, small cystic benign appearing lesion within pedicle of L3 ve. The outcome of the event of Guillain-Barre syndrome was unknown. The reporter assessed the event to be serious with seriousness criteria of Life threatening and Hospitalization.
Age: 9.0
Sex: F
Vaccine: FLUN3
Symptoms: Computerised tomogram, Crystal urine, Demyelinating polyneuropathy, Diplopia, Electromyogram abnormal
Clinical narrative: This report to VAERS provides the following narrative: A report has been received from consumer via VAERS concerning a 9 year old female patient. The patient's concurrent disease included allergic rhinitis. Concomitant medications included cetirizine hydrochloride. Patient had been receiving FLUMIST (intranasal) started on 10-Jan-2013. Odd gait when walking, running on 01-Apr-2013. Feet tingled on 02-Apr-2013. Limping on 03-Apr-2013 and began falling frequently. ER on 07-Apr-2013 and diagnosed with Guillain-Barre Syndrome on 08-Apr-2013. The following information was obtained through follow-up and/or provided by the government. 13-Jun-2013 Hospital records and discharge summary received. Service dates 07-Apr-2013 to 16-Apr-2013, 24-Apr-2013 to 09-May-2013. Diagnosis: Guillain-Barre Syndrome, axonal variant, with associated lower extremity weakness, relapse. Acute demyelinating polyneuropathy. Patient diagnosed with GBS 2 weeks prior, clumsiness, difficulties walking, foot numbness/tingling. IVIG administration. Using walker, discharged to outpatient PT/OT. Now presenting with worsening weakness in lower extremities and new tingling in feet. Blurred/double vision and weakness in EOM, CN 6 Palsy. Areflexia lower extremities with weakness in hips, knees, ankles. Back/neck pain. Potential Miller-Fisher. Gabapentin PO. Trouble sleeping. Urinary retention, bladder distended, probable neurogenic bladder. Plasmapheresis catheter placement, PLEX. 6/14/13 Neurology Consultation records received. Service dates 16-Apr-2013 to 02-May-2013. Additional Information Abstracted: Diagnosis: Guillain-Barre Syndrome. Worsening balance, difficulty walking, worsening weakness lower extremities. Weakness noted involving bilateral upper extremities. Emesis, pain in hips and neck, neuropathic pain, headache after IVIG, transient hypotension, anxious. Keratosis pilaris. Plasma exchanges. CT Scan. Full blood work. MRI and spinal tap. The following information was obtained through follow-up and/or provided by the government. 13-Jun-2013, 21-Jun-2013, 24-Jun-2013 Labs and Diagnostics: CSF - Abnormal, Protein 135 mg/dl. CBC / RBC 3.74 M/mm3 (L) HGB 11.0 g/dl (L) HCT 32.4% (L) RDW 16.1% (H) Seg 35.8% (L) Mono 11.0% (H) Lymph 48.6% (H). Sed Rate 86 mm/hr (H). Fibrinogen 143 mg/dl (L). CHEM - Calcium Ionized 1.35 mm/L (H) ALT 68 (H) AST 56 (H). Urinalysis - Cloudy, Leukocytes trace, Amorphous crystals few, Gram Stain positive cocci in pairs, Gram negative coccobacilli. EMG/NCS report with graphs - Abnormal. MRI Spine - Abnormal, enhancement of lumbosacral/cauda equina nerve roots, small cystic benign appearing lesion within pedicle of L3 ve. The outcome of the event of Guillain-Barre syndrome was unknown. The reporter assessed the event to be serious with seriousness criteria of Life threatening and Hospitalization.
Age: 9.0
Sex: F
Vaccine: FLUN3
Symptoms: Fall, Full blood count, Gait disturbance, Gram stain positive, Guillain-Barre syndrome
Clinical narrative: This report to VAERS provides the following narrative: A report has been received from consumer via VAERS concerning a 9 year old female patient. The patient's concurrent disease included allergic rhinitis. Concomitant medications included cetirizine hydrochloride. Patient had been receiving FLUMIST (intranasal) started on 10-Jan-2013. Odd gait when walking, running on 01-Apr-2013. Feet tingled on 02-Apr-2013. Limping on 03-Apr-2013 and began falling frequently. ER on 07-Apr-2013 and diagnosed with Guillain-Barre Syndrome on 08-Apr-2013. The following information was obtained through follow-up and/or provided by the government. 13-Jun-2013 Hospital records and discharge summary received. Service dates 07-Apr-2013 to 16-Apr-2013, 24-Apr-2013 to 09-May-2013. Diagnosis: Guillain-Barre Syndrome, axonal variant, with associated lower extremity weakness, relapse. Acute demyelinating polyneuropathy. Patient diagnosed with GBS 2 weeks prior, clumsiness, difficulties walking, foot numbness/tingling. IVIG administration. Using walker, discharged to outpatient PT/OT. Now presenting with worsening weakness in lower extremities and new tingling in feet. Blurred/double vision and weakness in EOM, CN 6 Palsy. Areflexia lower extremities with weakness in hips, knees, ankles. Back/neck pain. Potential Miller-Fisher. Gabapentin PO. Trouble sleeping. Urinary retention, bladder distended, probable neurogenic bladder. Plasmapheresis catheter placement, PLEX. 6/14/13 Neurology Consultation records received. Service dates 16-Apr-2013 to 02-May-2013. Additional Information Abstracted: Diagnosis: Guillain-Barre Syndrome. Worsening balance, difficulty walking, worsening weakness lower extremities. Weakness noted involving bilateral upper extremities. Emesis, pain in hips and neck, neuropathic pain, headache after IVIG, transient hypotension, anxious. Keratosis pilaris. Plasma exchanges. CT Scan. Full blood work. MRI and spinal tap. The following information was obtained through follow-up and/or provided by the government. 13-Jun-2013, 21-Jun-2013, 24-Jun-2013 Labs and Diagnostics: CSF - Abnormal, Protein 135 mg/dl. CBC / RBC 3.74 M/mm3 (L) HGB 11.0 g/dl (L) HCT 32.4% (L) RDW 16.1% (H) Seg 35.8% (L) Mono 11.0% (H) Lymph 48.6% (H). Sed Rate 86 mm/hr (H). Fibrinogen 143 mg/dl (L). CHEM - Calcium Ionized 1.35 mm/L (H) ALT 68 (H) AST 56 (H). Urinalysis - Cloudy, Leukocytes trace, Amorphous crystals few, Gram Stain positive cocci in pairs, Gram negative coccobacilli. EMG/NCS report with graphs - Abnormal. MRI Spine - Abnormal, enhancement of lumbosacral/cauda equina nerve roots, small cystic benign appearing lesion within pedicle of L3 ve. The outcome of the event of Guillain-Barre syndrome was unknown. The reporter assessed the event to be serious with seriousness criteria of Life threatening and Hospitalization.
Age: 9.0
Sex: F
Vaccine: FLUN3
Symptoms: Haematocrit decreased, Haemoglobin decreased, Headache, Hypoaesthesia, Hypotension
Clinical narrative: This report to VAERS provides the following narrative: A report has been received from consumer via VAERS concerning a 9 year old female patient. The patient's concurrent disease included allergic rhinitis. Concomitant medications included cetirizine hydrochloride. Patient had been receiving FLUMIST (intranasal) started on 10-Jan-2013. Odd gait when walking, running on 01-Apr-2013. Feet tingled on 02-Apr-2013. Limping on 03-Apr-2013 and began falling frequently. ER on 07-Apr-2013 and diagnosed with Guillain-Barre Syndrome on 08-Apr-2013. The following information was obtained through follow-up and/or provided by the government. 13-Jun-2013 Hospital records and discharge summary received. Service dates 07-Apr-2013 to 16-Apr-2013, 24-Apr-2013 to 09-May-2013. Diagnosis: Guillain-Barre Syndrome, axonal variant, with associated lower extremity weakness, relapse. Acute demyelinating polyneuropathy. Patient diagnosed with GBS 2 weeks prior, clumsiness, difficulties walking, foot numbness/tingling. IVIG administration. Using walker, discharged to outpatient PT/OT. Now presenting with worsening weakness in lower extremities and new tingling in feet. Blurred/double vision and weakness in EOM, CN 6 Palsy. Areflexia lower extremities with weakness in hips, knees, ankles. Back/neck pain. Potential Miller-Fisher. Gabapentin PO. Trouble sleeping. Urinary retention, bladder distended, probable neurogenic bladder. Plasmapheresis catheter placement, PLEX. 6/14/13 Neurology Consultation records received. Service dates 16-Apr-2013 to 02-May-2013. Additional Information Abstracted: Diagnosis: Guillain-Barre Syndrome. Worsening balance, difficulty walking, worsening weakness lower extremities. Weakness noted involving bilateral upper extremities. Emesis, pain in hips and neck, neuropathic pain, headache after IVIG, transient hypotension, anxious. Keratosis pilaris. Plasma exchanges. CT Scan. Full blood work. MRI and spinal tap. The following information was obtained through follow-up and/or provided by the government. 13-Jun-2013, 21-Jun-2013, 24-Jun-2013 Labs and Diagnostics: CSF - Abnormal, Protein 135 mg/dl. CBC / RBC 3.74 M/mm3 (L) HGB 11.0 g/dl (L) HCT 32.4% (L) RDW 16.1% (H) Seg 35.8% (L) Mono 11.0% (H) Lymph 48.6% (H). Sed Rate 86 mm/hr (H). Fibrinogen 143 mg/dl (L). CHEM - Calcium Ionized 1.35 mm/L (H) ALT 68 (H) AST 56 (H). Urinalysis - Cloudy, Leukocytes trace, Amorphous crystals few, Gram Stain positive cocci in pairs, Gram negative coccobacilli. EMG/NCS report with graphs - Abnormal. MRI Spine - Abnormal, enhancement of lumbosacral/cauda equina nerve roots, small cystic benign appearing lesion within pedicle of L3 ve. The outcome of the event of Guillain-Barre syndrome was unknown. The reporter assessed the event to be serious with seriousness criteria of Life threatening and Hospitalization.
Age: 9.0
Sex: F
Vaccine: FLUN3
Symptoms: Immunoglobulin therapy, Insomnia, Keratosis pilaris, Lumbar puncture, Lymphocyte percentage increased
Clinical narrative: This report to VAERS provides the following narrative: A report has been received from consumer via VAERS concerning a 9 year old female patient. The patient's concurrent disease included allergic rhinitis. Concomitant medications included cetirizine hydrochloride. Patient had been receiving FLUMIST (intranasal) started on 10-Jan-2013. Odd gait when walking, running on 01-Apr-2013. Feet tingled on 02-Apr-2013. Limping on 03-Apr-2013 and began falling frequently. ER on 07-Apr-2013 and diagnosed with Guillain-Barre Syndrome on 08-Apr-2013. The following information was obtained through follow-up and/or provided by the government. 13-Jun-2013 Hospital records and discharge summary received. Service dates 07-Apr-2013 to 16-Apr-2013, 24-Apr-2013 to 09-May-2013. Diagnosis: Guillain-Barre Syndrome, axonal variant, with associated lower extremity weakness, relapse. Acute demyelinating polyneuropathy. Patient diagnosed with GBS 2 weeks prior, clumsiness, difficulties walking, foot numbness/tingling. IVIG administration. Using walker, discharged to outpatient PT/OT. Now presenting with worsening weakness in lower extremities and new tingling in feet. Blurred/double vision and weakness in EOM, CN 6 Palsy. Areflexia lower extremities with weakness in hips, knees, ankles. Back/neck pain. Potential Miller-Fisher. Gabapentin PO. Trouble sleeping. Urinary retention, bladder distended, probable neurogenic bladder. Plasmapheresis catheter placement, PLEX. 6/14/13 Neurology Consultation records received. Service dates 16-Apr-2013 to 02-May-2013. Additional Information Abstracted: Diagnosis: Guillain-Barre Syndrome. Worsening balance, difficulty walking, worsening weakness lower extremities. Weakness noted involving bilateral upper extremities. Emesis, pain in hips and neck, neuropathic pain, headache after IVIG, transient hypotension, anxious. Keratosis pilaris. Plasma exchanges. CT Scan. Full blood work. MRI and spinal tap. The following information was obtained through follow-up and/or provided by the government. 13-Jun-2013, 21-Jun-2013, 24-Jun-2013 Labs and Diagnostics: CSF - Abnormal, Protein 135 mg/dl. CBC / RBC 3.74 M/mm3 (L) HGB 11.0 g/dl (L) HCT 32.4% (L) RDW 16.1% (H) Seg 35.8% (L) Mono 11.0% (H) Lymph 48.6% (H). Sed Rate 86 mm/hr (H). Fibrinogen 143 mg/dl (L). CHEM - Calcium Ionized 1.35 mm/L (H) ALT 68 (H) AST 56 (H). Urinalysis - Cloudy, Leukocytes trace, Amorphous crystals few, Gram Stain positive cocci in pairs, Gram negative coccobacilli. EMG/NCS report with graphs - Abnormal. MRI Spine - Abnormal, enhancement of lumbosacral/cauda equina nerve roots, small cystic benign appearing lesion within pedicle of L3 ve. The outcome of the event of Guillain-Barre syndrome was unknown. The reporter assessed the event to be serious with seriousness criteria of Life threatening and Hospitalization.
Age: 9.0
Sex: F
Vaccine: FLUN3
Symptoms: Muscular weakness, Neck pain, Nerve conduction studies abnormal, Neuralgia, Neurogenic bladder
Clinical narrative: This report to VAERS provides the following narrative: A report has been received from consumer via VAERS concerning a 9 year old female patient. The patient's concurrent disease included allergic rhinitis. Concomitant medications included cetirizine hydrochloride. Patient had been receiving FLUMIST (intranasal) started on 10-Jan-2013. Odd gait when walking, running on 01-Apr-2013. Feet tingled on 02-Apr-2013. Limping on 03-Apr-2013 and began falling frequently. ER on 07-Apr-2013 and diagnosed with Guillain-Barre Syndrome on 08-Apr-2013. The following information was obtained through follow-up and/or provided by the government. 13-Jun-2013 Hospital records and discharge summary received. Service dates 07-Apr-2013 to 16-Apr-2013, 24-Apr-2013 to 09-May-2013. Diagnosis: Guillain-Barre Syndrome, axonal variant, with associated lower extremity weakness, relapse. Acute demyelinating polyneuropathy. Patient diagnosed with GBS 2 weeks prior, clumsiness, difficulties walking, foot numbness/tingling. IVIG administration. Using walker, discharged to outpatient PT/OT. Now presenting with worsening weakness in lower extremities and new tingling in feet. Blurred/double vision and weakness in EOM, CN 6 Palsy. Areflexia lower extremities with weakness in hips, knees, ankles. Back/neck pain. Potential Miller-Fisher. Gabapentin PO. Trouble sleeping. Urinary retention, bladder distended, probable neurogenic bladder. Plasmapheresis catheter placement, PLEX. 6/14/13 Neurology Consultation records received. Service dates 16-Apr-2013 to 02-May-2013. Additional Information Abstracted: Diagnosis: Guillain-Barre Syndrome. Worsening balance, difficulty walking, worsening weakness lower extremities. Weakness noted involving bilateral upper extremities. Emesis, pain in hips and neck, neuropathic pain, headache after IVIG, transient hypotension, anxious. Keratosis pilaris. Plasma exchanges. CT Scan. Full blood work. MRI and spinal tap. The following information was obtained through follow-up and/or provided by the government. 13-Jun-2013, 21-Jun-2013, 24-Jun-2013 Labs and Diagnostics: CSF - Abnormal, Protein 135 mg/dl. CBC / RBC 3.74 M/mm3 (L) HGB 11.0 g/dl (L) HCT 32.4% (L) RDW 16.1% (H) Seg 35.8% (L) Mono 11.0% (H) Lymph 48.6% (H). Sed Rate 86 mm/hr (H). Fibrinogen 143 mg/dl (L). CHEM - Calcium Ionized 1.35 mm/L (H) ALT 68 (H) AST 56 (H). Urinalysis - Cloudy, Leukocytes trace, Amorphous crystals few, Gram Stain positive cocci in pairs, Gram negative coccobacilli. EMG/NCS report with graphs - Abnormal. MRI Spine - Abnormal, enhancement of lumbosacral/cauda equina nerve roots, small cystic benign appearing lesion within pedicle of L3 ve. The outcome of the event of Guillain-Barre syndrome was unknown. The reporter assessed the event to be serious with seriousness criteria of Life threatening and Hospitalization.